Loading
companiesCompany
Pharmacosmos
Pharmacosmos is a Danish family-owned company specialising in intravenous iron; its iron isomaltoside (Monofer) treats the anaemia that chemotherapy and cancer itself cause, and it leads phase 3 trials in that setting.
Also called: Pharmacosmos A/S
Overview
Pharmacosmos A/S, founded in 1965 and based in Holbæk, Denmark, develops carbohydrate chemistry and intravenous iron products. Its iron isomaltoside 1000 (Monofer, ferric derisomaltose in the United States) is given as a single high-dose infusion for iron deficiency anaemia, including in patients with cancer, and the company has run phase 3 trials in cancer-related anaemia registered on ClinicalTrials.gov.
Headquarters
Holbæk, DK
Scorecard
All companies#222of 1244 companies, score 24
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +13
1 approved, 0 in phase 3, 0 earlier, 1 targets, 40 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Founded
1965
ApprovedIntravenous CDK4/6 inhibitor given before chemotherapy to protect bone marrow
Trilaciclib · Cosela
Trilaciclib is given as an infusion just before chemotherapy for small cell lung cancer to put the bone marrow's stem cells briefly to sleep, so fewer are killed and patients need fewer transfusions and growth factor injections.
Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
fronts
drugs
ApprovedIntravenous CDK4/6 inhibitor given before chemotherapy to protect bone marrow
Trilaciclib · Cosela